Please Wait
Applying Filters...
menu
    • menu
    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Larsucosterol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Durect Corportion Announces Larsucosterol Phase 3 Trial Design
    Durect Corportion Announces Larsucosterol Phase 3 Trial Design

    25 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/durect-corporation-announces-phase-3-registrational-trial-design-for-larsucosterol-in-alcohol-associated-hepatitis-302258033.html

    PR NEWSWIRE
    25 Sep 2024
    Share Share
    DURECT Gets FDA Breakthrough For Larsucosterol In Alcoholic Hepatitis
    DURECT Gets FDA Breakthrough For Larsucosterol In Alcoholic Hepatitis

    21 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/durect-corporation-receives-fda-breakthrough-therapy-designation-for-larsucosterol-in-alcohol-associated-hepatitis-302150934.html

    PR NEWSWIRE
    21 May 2024
    Share Share
    DURECT Corporation Announces Results from Phase 2b Trial of Larsucosterol
    DURECT Corporation Announces Results from Phase 2b Trial of Larsucosterol

    07 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/durect-corporation-announces-topline-results-from-phase-2b-ahfirm-trial-of-larsucosterol-in-alcohol-associated-hepatitis-with-promising-effect-on-mortality-301980628.html

    PR NEWSWIRE
    07 Nov 2023
    Share Share
    DURECT Announces Last Patient Last Visit in Ph 2b AHFIRM Trial of Larsucosterol
    DURECT Announces Last Patient Last Visit in Ph 2b AHFIRM Trial of Larsucosterol

    07 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/durect-corporation-announces-last-patient-last-visit-in-phase-2b-ahfirm-trial-of-larsucosterol-in-alcohol-associated-hepatitis-301920265.html

    PR NEWSWIRE
    07 Sep 2023
    Share Share
    DURECT concludes patient enrolment in Phase IIb trial of AH therapy
    DURECT concludes patient enrolment in Phase IIb trial of AH therapy

    08 Jun 2023

    // CLINICAL TRIALS ARENA

    https://www.clinicaltrialsarena.com/news/durect-concludes-enrolment-ah-therapy/

    CLINICAL TRIALS ARENA
    08 Jun 2023
    Share Share
    DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol
    DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol

    07 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/durect-completes-enrollment-in-phase-2b-ahfirm-trial-of-larsucosterol-in-alcohol-associated-hepatitis-301844490.html

    PR NEWSWIRE
    07 Jun 2023
    Share Share